During the past years, immune checkpoint inhibitors suppressing the PD-1/PD-L1 pathway improved prognosis in different tumor entities significantly and became first line treatment in metastatic melanoma, NSCLC, HNSCC, renal and bladder cancer (4, 5, 16–18). This evidence concerns the gene PDCD1 and urinary bladder carcinoma.